The association with long-term mortality of different pharmacological agents, age, sex and index year in patients discharged and alive at 30 days after hospitalisation for acute aortic dissection, analysed with Cox proportional hazards models
| Total at start, n (%) | Crude HR (95% CI) | Adjusted HR (95% CI) | |
| (A) | |||
| Men | 1948 (64) | 1 | 1 |
| Women | 1098 (36) | 1.31 (1.13 to 1.51) | 0.99 (0.86 to 1.15) |
| Age categories | |||
| 18–49 | 306 (10) | 1 | 1 |
| 50–59 | 532 (17) | 1.54 (0.92 to 2.56) | 1.57 (0.94 to 2.64) |
| 60–69 | 932 (31) | 3.10 (1.94 to 4.90) | 3.02 (1.89 to 4.92) |
| 70–79 | 803 (26) | 6.32 (4.10 to 10.10) | 5.99 (3.77 to 9.51) |
| 80–99 | 473 (16) | 16.40 (10.40 to 25.88) | 13.60 (8.54 to 21.66) |
| Index year | |||
| 2005–2010 | 1416 (47) | 1 | 1 |
| 2011–2015 | 1630 (53) | 0.87 (0.74 to 1.04) | 0.92 (0.78 to 1.10) |
| Any antihypertensive | |||
| No | 107 (4) | 1 | 1 |
| Yes | 2939 (96) | 0.57 (0.41 to 0.79) | 0.56 (0.43 to 0.84) |
| Statin | |||
| No | 1628 (53) | 1 | 1 |
| Yes | 1418 (47) | 0.71 (0.61 to 0.82) | 0.74 (0.63 to 0.87) |
| Anticoagulant | |||
| No | 2362 (77) | 1 | 1 |
| Yes | 684 (23) | 0.80 (0.67 to 0.96) | 0.83 (0.68 to 1.03) |
| Antiplatelet therapy | |||
| No | 1622 (53) | 1 | 1 |
| Yes | 1424 (47) | 1.07 (0.92 to 1.23) | 1.03 (0.87 to 1.20) |
| (B) | |||
| Beta blocker | |||
| No | 305 (10) | 1 | 1 |
| Yes | 2741 (90) | 0.60 (0.49 to 0.75) | 0.82 (0.66 to 1.03) |
| Calcium channel blocker | |||
| No | 755 (25) | 1 | 1 |
| Yes | 2291 (75) | 0.73 (0.63 to 0.86) | 0.81 (0.68 to 0.96) |
| ACE inhibitor | |||
| No | 1494 (49) | 1 | 1 |
| Yes | 1552 (51) | 0.81 (0.71 to 0.94) | 0.81 (0.70 to 0.95) |
| ARB | |||
| No | 2153 (71) | 1 | 1 |
| Yes | 893 (29) | 0.71 (0.61 to 0.85) | 0.76 (0.63 to 0.92) |
| Diuretic | |||
| No | 944 (31) | 1 | 1 |
| Yes | 2102 (69) | 1.13 (0.97 to 1.32) | 1.23 (1.03 to 1.47) |
All multivariable Cox proportional hazards models were adjusted for age, sex, index year, concomitant disorders (hypertension, ischaemic heart disease, heart failure, atrial fibrillation, ischaemic stroke, peripheral arterial disease, kidney failure and diabetes) and all other listed pharmacological groups in each specific analysis.
In part A, antihypertensive medication is presented as one single variable, whereas in part B, the different antihypertensive drugs were analysed separately
ARB, angiotensin II receptor blocker.